AU2008305294B2 - Pyridin-2 -yl-amino-1, 2, 4 -thiadiazole derivatives as glucokinase activators for the treatment of diabetes mellitus - Google Patents

Pyridin-2 -yl-amino-1, 2, 4 -thiadiazole derivatives as glucokinase activators for the treatment of diabetes mellitus Download PDF

Info

Publication number
AU2008305294B2
AU2008305294B2 AU2008305294A AU2008305294A AU2008305294B2 AU 2008305294 B2 AU2008305294 B2 AU 2008305294B2 AU 2008305294 A AU2008305294 A AU 2008305294A AU 2008305294 A AU2008305294 A AU 2008305294A AU 2008305294 B2 AU2008305294 B2 AU 2008305294B2
Authority
AU
Australia
Prior art keywords
alkyl
pyridin
compound
formula
yloxy
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
AU2008305294A
Other languages
English (en)
Other versions
AU2008305294A1 (en
Inventor
Thomas Daniel Aicher
Steven Armen Boyd
Mark Joseph Chicarelli
Kevin Ronald Condroski
Jay Bradford Fell
John P. Fischer
Indrani W. Gunawardana
Ronald Jay Hinklin
Ajay Singh
Timothy M. Turner
Eli M. Wallace
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Array Biopharma Inc
Original Assignee
Array Biopharma Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Array Biopharma Inc filed Critical Array Biopharma Inc
Publication of AU2008305294A1 publication Critical patent/AU2008305294A1/en
Application granted granted Critical
Publication of AU2008305294B2 publication Critical patent/AU2008305294B2/en
Ceased legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/72—Nitrogen atoms
    • C07D213/75—Amino or imino radicals, acylated by carboxylic or carbonic acids, or by sulfur or nitrogen analogues thereof, e.g. carbamates
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Diabetes (AREA)
  • Public Health (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pyridine Compounds (AREA)
AU2008305294A 2007-09-21 2008-09-15 Pyridin-2 -yl-amino-1, 2, 4 -thiadiazole derivatives as glucokinase activators for the treatment of diabetes mellitus Ceased AU2008305294B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US97422507P 2007-09-21 2007-09-21
US60/974,225 2007-09-21
PCT/US2008/076401 WO2009042435A1 (en) 2007-09-21 2008-09-15 Pyridin-2 -yl-amino-i, 2, 4 -thiadiazole derivatives as glucokinase activators for the treatment of diabetes mellitus

Publications (2)

Publication Number Publication Date
AU2008305294A1 AU2008305294A1 (en) 2009-04-02
AU2008305294B2 true AU2008305294B2 (en) 2012-11-29

Family

ID=40250949

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2008305294A Ceased AU2008305294B2 (en) 2007-09-21 2008-09-15 Pyridin-2 -yl-amino-1, 2, 4 -thiadiazole derivatives as glucokinase activators for the treatment of diabetes mellitus

Country Status (28)

Country Link
US (3) US8212045B2 (cg-RX-API-DMAC7.html)
EP (4) EP3078662A1 (cg-RX-API-DMAC7.html)
JP (1) JP5722037B2 (cg-RX-API-DMAC7.html)
KR (1) KR101566042B1 (cg-RX-API-DMAC7.html)
CN (1) CN101868459B (cg-RX-API-DMAC7.html)
AR (1) AR068628A1 (cg-RX-API-DMAC7.html)
AU (1) AU2008305294B2 (cg-RX-API-DMAC7.html)
BR (1) BRPI0816881A2 (cg-RX-API-DMAC7.html)
CA (1) CA2699718C (cg-RX-API-DMAC7.html)
CO (1) CO6270223A2 (cg-RX-API-DMAC7.html)
CR (2) CR11383A (cg-RX-API-DMAC7.html)
DK (1) DK2209778T3 (cg-RX-API-DMAC7.html)
EA (1) EA019104B1 (cg-RX-API-DMAC7.html)
ES (2) ES2569734T3 (cg-RX-API-DMAC7.html)
HR (1) HRP20120814T1 (cg-RX-API-DMAC7.html)
IL (1) IL204264A (cg-RX-API-DMAC7.html)
MA (1) MA31779B1 (cg-RX-API-DMAC7.html)
MX (1) MX2010002772A (cg-RX-API-DMAC7.html)
MY (1) MY180558A (cg-RX-API-DMAC7.html)
NZ (1) NZ583538A (cg-RX-API-DMAC7.html)
PL (1) PL2209778T3 (cg-RX-API-DMAC7.html)
PT (1) PT2209778E (cg-RX-API-DMAC7.html)
SI (1) SI2209778T1 (cg-RX-API-DMAC7.html)
TN (1) TN2010000100A1 (cg-RX-API-DMAC7.html)
TW (1) TWI423799B (cg-RX-API-DMAC7.html)
UA (1) UA101166C2 (cg-RX-API-DMAC7.html)
WO (1) WO2009042435A1 (cg-RX-API-DMAC7.html)
ZA (2) ZA201002206B (cg-RX-API-DMAC7.html)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2131656A4 (en) * 2006-11-15 2011-12-07 Forest Lab Holdings Ltd phthalazine
EA019104B1 (ru) 2007-09-21 2014-01-30 Эррей Биофарма Инк. Активаторы глюкокиназы
WO2011107494A1 (de) 2010-03-03 2011-09-09 Sanofi Neue aromatische glykosidderivate, diese verbindungen enthaltende arzneimittel und deren verwendung
CA2800498C (en) 2010-03-31 2021-11-16 The Scripps Research Institute Reprogramming cells
US8530413B2 (en) 2010-06-21 2013-09-10 Sanofi Heterocyclically substituted methoxyphenyl derivatives with an oxo group, processes for preparation thereof and use thereof as medicaments
TW201215388A (en) 2010-07-05 2012-04-16 Sanofi Sa (2-aryloxyacetylamino)phenylpropionic acid derivatives, processes for preparation thereof and use thereof as medicaments
TW201221505A (en) 2010-07-05 2012-06-01 Sanofi Sa Aryloxyalkylene-substituted hydroxyphenylhexynoic acids, process for preparation thereof and use thereof as a medicament
TW201215387A (en) 2010-07-05 2012-04-16 Sanofi Aventis Spirocyclically substituted 1,3-propane dioxide derivatives, processes for preparation thereof and use thereof as a medicament
MX2013002208A (es) 2010-08-23 2013-05-30 Amgen Inc Derivados de sulfonilpiperazina que interactuan con la proteina reguladora de glucocinasa para el tratamiento de diabetes.
KR20140051834A (ko) 2011-03-09 2014-05-02 다이이찌 산쿄 가부시키가이샤 디피리딜아민 유도체
WO2012138776A1 (en) 2011-04-05 2012-10-11 Amgen Inc. Benzodioxepine and benzodioxine compounds that interact with glucokinase regulatory protein for the treatment of diabetes
WO2013037390A1 (en) 2011-09-12 2013-03-21 Sanofi 6-(4-hydroxy-phenyl)-3-styryl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors
EP2760862B1 (en) 2011-09-27 2015-10-21 Sanofi 6-(4-hydroxy-phenyl)-3-alkyl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors
CN104230892B (zh) * 2011-11-09 2016-12-07 福建海西新药创制有限公司 一组提高激酶活性的化合物及其应用
WO2013123444A1 (en) 2012-02-17 2013-08-22 Amgen Inc. Sulfonyl compounds that interact with glucokinase regulatory protein
WO2013173382A1 (en) 2012-05-15 2013-11-21 Amgen Inc. Benzothiophene sulfonamides and other compounds that interact with glucokinase regulatory protein
EP2850057A4 (en) * 2012-05-18 2016-01-27 Amgen Inc PROCESS FOR THE PREPARATION OF THIADIAZOLENE
US20150299182A1 (en) * 2012-11-09 2015-10-22 Amgen Inc. Crystalline forms of (1s)-1-[5-(amino)-1,2,4-thiadiazol-3-yl]ethane-1,2-diol
WO2016059647A2 (en) * 2014-10-13 2016-04-21 SHRI CHHATRAPTI SHIVAJI COLLEGE Maharashtra, India) Triaminotriazine picolinonitrile derivatives as potent reverse transcriptase inhibitor of hiv-1
GB201714777D0 (en) 2017-09-14 2017-11-01 Univ London Queen Mary Agent
BR112020008727A2 (pt) 2017-10-30 2020-10-20 Neuropore Therapies, Inc. fenil sulfonil fenil triazol tionas substituídas e usos destas
BR112020024269A2 (pt) * 2018-05-31 2021-02-23 Hua Medicine (Shanghai) Ltd. combinação farmacêutica, composição e formulação de combinação contendo ativador de glucoquinase e ativador de receptor ppar e métodos de preparação e usos dos mesmos

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007117381A2 (en) * 2006-03-24 2007-10-18 Array Biopharma Inc. 2 -aminopyridine analogs as glucokinase activators
WO2008118718A2 (en) * 2007-03-23 2008-10-02 Array Biopharma Inc. 2-aminopyridine analogs as glucokinase activators

Family Cites Families (80)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3983246A (en) 1974-04-04 1976-09-28 Fmc Corporation N-(sulfonyloxy) benzimidoyl halides as bactericidal or fungicidal agents
DE2949913A1 (de) * 1979-12-12 1981-06-25 Basf Ag, 6700 Ludwigshafen Azofarbstoffe
EP0300688A1 (en) 1987-07-21 1989-01-25 FISONS plc Pyrrole derivatives, process for their preparation and pharmaceutical compositions containing them
JPH0228168A (ja) * 1988-04-14 1990-01-30 Sankyo Co Ltd チアゾール誘導体
WO1993017681A1 (en) 1992-03-02 1993-09-16 Abbott Laboratories Angiotensin ii receptor antagonists
WO1993024442A1 (fr) 1992-05-29 1993-12-09 Yamanouchi Pharmaceutical Co., Ltd. Medicament renfermant un derive d'acide benzoique, et nouveau derive d'acide benzoique
JP3056788B2 (ja) 1994-06-24 2000-06-26 ユーロ−セルティーク,エス.エイ. ホスホジエステラーゼivの阻害化合物および阻害方法
GB9908410D0 (en) * 1999-04-13 1999-06-09 Pfizer Ltd Pyridines
CA2366932C (en) 1999-04-15 2009-08-25 Bristol-Myers Squibb Company Cyclic protein tyrosine kinase inhibitors
US7125875B2 (en) 1999-04-15 2006-10-24 Bristol-Myers Squibb Company Cyclic protein tyrosine kinase inhibitors
HRP20010795A2 (en) 1999-04-28 2003-02-28 Aventis Pharma Gmbh Di-aryl acid derivatives as ppar receptor ligands
US6465467B1 (en) 1999-05-21 2002-10-15 Biovitrum Ab Certain aryl-aliphatic and heteroaryl-aliphatic piperazinyl pyrazines and their use in the treatment of serotonin-related diseases
CA2374898C (en) 1999-05-21 2009-12-08 Biovitrum Ab Pyrazinyl-piperazine compounds, their use and preparation
JP4144978B2 (ja) 1999-09-09 2008-09-03 富士フイルム株式会社 1,2,4−チアジアゾール誘導体の合成法
MXPA02002559A (es) 1999-09-10 2002-07-30 Merck & Co Inc Inhibidores de tirosina cinasa.
CA2396693A1 (en) 1999-12-28 2001-07-05 Stephen T. Wrobleski Cytokine, especially tnf-alpha, inhibitors
US6906067B2 (en) 1999-12-28 2005-06-14 Bristol-Myers Squibb Company N-heterocyclic inhibitors of TNF-α expression
US20020065270A1 (en) 1999-12-28 2002-05-30 Moriarty Kevin Joseph N-heterocyclic inhibitors of TNF-alpha expression
US7345051B2 (en) 2000-01-31 2008-03-18 Genaera Corporation Mucin synthesis inhibitors
DZ3398A1 (fr) 2000-08-31 2002-03-07 Pfizer Prod Inc Derives pyrazole et leur utilisation comme inhibiteurs des proteines kinases
US20050209297A1 (en) 2000-08-31 2005-09-22 Pfizer Inc Pyrazole derivatives
AU2002213467A1 (en) 2000-10-11 2002-04-22 Chemocentryx, Inc. Modulation of ccr4 function
WO2002030357A2 (en) 2000-10-11 2002-04-18 Chemocentryx, Inc. Compounds and methods for modulating ccr4 function
AU3950802A (en) 2000-12-07 2002-06-18 Cv Therapeutics Inc Abca-1 elevating compounds
BR0116493A (pt) 2000-12-21 2003-09-30 Vertex Pharma Compostos de pirazol úteis como inibidores de proteìna cinase
AU2002258400A1 (en) 2001-02-16 2002-08-28 Tularik Inc. Methods of using pyrimidine-based antiviral agents
WO2002094264A1 (en) 2001-05-23 2002-11-28 Tularik Inc. Ccr4 antagonists
CA2450934A1 (en) 2001-06-19 2002-12-27 Marco Dodier Pyrimidine inhibitors of phosphodiesterase (pde) 7
PE20030008A1 (es) 2001-06-19 2003-01-22 Bristol Myers Squibb Co Inhibidores duales de pde 7 y pde 4
ATE316088T1 (de) * 2001-06-22 2006-02-15 Merck & Co Inc Tyrosin-kinase inhibitoren
EP1465900B1 (en) 2002-01-10 2008-05-14 Bayer HealthCare AG Rho-kinase inhibitors
ATE511858T1 (de) 2002-02-05 2011-06-15 Astellas Pharma Inc 2,4,6-triamino-1,3,5-triazin-derivat
US6846928B2 (en) 2002-03-15 2005-01-25 Vertex Pharmaceuticals Incorporated Compositions useful as inhibitors of protein kinases
AU2003225800A1 (en) 2002-03-15 2003-09-29 Hayley Binch Azolylaminoazine as inhibitors of protein kinases
US20040009981A1 (en) 2002-03-15 2004-01-15 David Bebbington Compositions useful as inhibitors of protein kinases
WO2003077921A1 (en) 2002-03-15 2003-09-25 Vertex Pharmaceuticals, Inc. Azinylaminoazoles as inhibitors of protein kinases
MXPA04009541A (es) 2002-03-29 2005-01-25 Chiron Corp Benzazoles sustituidos y uso de los mismos como inhibidores de cinasa raf.
US8299108B2 (en) 2002-03-29 2012-10-30 Novartis Ag Substituted benzazoles and methods of their use as inhibitors of raf kinase
AU2003227360A1 (en) * 2002-04-25 2003-11-10 Yamanouchi Pharmaceutical Co., Ltd. Novel amide derivatives or salts thereof
AU2003249369A1 (en) 2002-06-21 2004-01-06 Cellular Genomics, Inc. Certain amino-substituted monocycles as kinase modulators
CN1691944A (zh) 2002-08-09 2005-11-02 阿斯利康(瑞典)有限公司 作为代谢型谷氨酸受体-5调节剂的噁二唑
WO2004024159A1 (en) 2002-09-10 2004-03-25 Scios Inc. INHIBITORS OF TFGβ
PL375021A1 (en) 2002-10-03 2005-11-14 Novartis Ag Substituted (thiazol-2-yl) -amide or sulfonamide as glycokinase activators useful in the treatment of type 2 diabetes
EP1558609A4 (en) 2002-10-30 2008-05-28 Merck & Co Inc KINASE INHIBITORS
CA2755297A1 (en) 2003-02-10 2004-08-26 Vertex Pharmaceuticals Incorporated Processes for the preparation of n-heteroaryl-n-aryl-amines by reacting an n-aryl carbamic acid ester with a halo-heteroaryl and analogous processes
US20040248850A1 (en) 2003-02-11 2004-12-09 Kemia, Inc. Compounds for the treatment of HIV infection
BRPI0407283A (pt) 2003-02-13 2006-01-31 Banyu Pharma Co Ltd Composto, composição farmacêutica, e, agente ativador de glucoquinase, agentes terapêuticos e/ou agentes preventivos para diabetes melito e obesidade
ATE396731T1 (de) 2003-03-25 2008-06-15 Vertex Pharma Thiazole zur verwendung als inhibitoren von protein-kinasen
US7244763B2 (en) 2003-04-17 2007-07-17 Warner Lambert Company Llc Compounds that modulate PPAR activity and methods of preparation
CN1845915A (zh) 2003-09-02 2006-10-11 默克公司 作为亲代谢谷氨酸受体-5的调节剂的联吡啶胺和醚类化合物
US7470712B2 (en) 2004-01-21 2008-12-30 Bristol-Myers Squibb Company Amino-benzazoles as P2Y1 receptor inhibitors
WO2005077373A2 (en) 2004-02-03 2005-08-25 Astrazeneca Ab Treatment of gastro-esophageal reflux disease (gerd)
AR049418A1 (es) 2004-02-27 2006-08-02 Bayer Pharmaceuticals Corp Derivados de heteroarilaminopirazol y composiciones farmaceuticas para el tratamiento de la diabetes.
KR20050091462A (ko) 2004-03-12 2005-09-15 한국과학기술연구원 푸로피리미딘 화합물 및 이를 포함하는 ddr2 티로신키나아제 활성 저해제
AU2005223610B2 (en) 2004-03-23 2008-05-29 Banyu Pharmaceutical Co., Ltd. Substituted quinazoline or pyridopyrimidine derivative
US7781451B2 (en) 2004-04-02 2010-08-24 Novartis Ag Thiazolopyridine derivatives, pharmaceut ical conditions containing them and methods of treating glucokinase mediated conditions
US7642354B2 (en) 2004-04-13 2010-01-05 Icagen, Inc. Polycyclic pyrazines as potassium ion channel modulators
EP1737852A2 (en) 2004-04-13 2007-01-03 Icagen, Inc. Polycyclic pyridines as potassium ion channel modulators
TW200606129A (en) * 2004-07-26 2006-02-16 Chugai Pharmaceutical Co Ltd Novel cyclohexane derivative, its prodrug, its salt and diabetic therapeutic agent containing the same
EP1844023A1 (en) 2004-12-31 2007-10-17 Sk Chemicals Co., Ltd. Quinazoline derivatives for the treatment and prevention of diabetes and obesity
MX2007008434A (es) 2005-01-19 2007-07-25 Squibb Bristol Myers Co Derivados de 2-fenoxi-n-(1,3,4-tiadizol-2il)piridin-3-amina y compuestos relacionados como inhibidores del receptor p2y1 para el tratamiento de trastornos tromboembolicos.
DE102005025161A1 (de) 2005-06-01 2006-12-07 Phenion Gmbh & Co. Kg Derivate des Pyrimidins und Triazins und deren Verwendung
US7737151B2 (en) 2005-08-18 2010-06-15 Vertex Pharmaceuticals Incorporated Pyrazine kinase inhibitors
AU2006285834A1 (en) * 2005-08-31 2007-03-08 Astellas Pharma Inc. Thiazole derivative
WO2007038387A2 (en) 2005-09-23 2007-04-05 Yale University Compounds and methods for the treatment of viruses and cancer
EP1948652B1 (en) 2005-11-01 2011-08-24 Array Biopharma, Inc. Glucokinase activators
JP5249770B2 (ja) 2005-11-03 2013-07-31 バーテックス ファーマシューティカルズ インコーポレイテッド キナーゼインヒビターとして有用なアミノピリジン
KR20070052207A (ko) 2005-11-16 2007-05-21 주식회사 엘지생명과학 신규한 kdr 억제제
ATE508126T1 (de) 2005-11-16 2011-05-15 Vertex Pharma Als kinaseinhibitoren geeignete aminopyrimidine
JP5236499B2 (ja) * 2006-01-27 2013-07-17 アレイ バイオファーマ、インコーポレイテッド グルコキナーゼ活性化剤
WO2007131953A1 (en) 2006-05-12 2007-11-22 Ab Science A new process for the synthesis of 2-aminoxazole compounds
WO2008024963A1 (en) 2006-08-24 2008-02-28 Serenex, Inc. Benzene, pyridine, and pyridazine derivatives
TW200825060A (en) 2006-10-26 2008-06-16 Astrazeneca Ab Chemical compounds
JP5208123B2 (ja) 2006-12-08 2013-06-12 アイアールエム・リミテッド・ライアビリティ・カンパニー タンパク質キナーゼ阻害剤としての化合物および組成物
US8431713B2 (en) 2007-01-24 2013-04-30 Array Biopharma, Inc. 2-aminopyridine derivatives as glucokinase activators
ES2470341T3 (es) 2007-04-05 2014-06-23 Amgen, Inc Moduladores de la aurora cinasa y método de uso
US20090012091A1 (en) 2007-07-02 2009-01-08 Kinagen, Inc. Oximide derivatives and their therapeutical application
WO2009022171A1 (en) 2007-08-13 2009-02-19 Astrazeneca Ab Pyridinyiioxy pyridines as alk5 inhibitors
EA019104B1 (ru) 2007-09-21 2014-01-30 Эррей Биофарма Инк. Активаторы глюкокиназы
KR20100090250A (ko) 2007-10-09 2010-08-13 메르크 파텐트 게엠베하 글루코키나제 활성체로서 유용한 피리딘 유도체

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007117381A2 (en) * 2006-03-24 2007-10-18 Array Biopharma Inc. 2 -aminopyridine analogs as glucokinase activators
WO2008118718A2 (en) * 2007-03-23 2008-10-02 Array Biopharma Inc. 2-aminopyridine analogs as glucokinase activators

Also Published As

Publication number Publication date
US9079890B2 (en) 2015-07-14
US8212045B2 (en) 2012-07-03
ZA201002206B (en) 2011-06-29
CN101868459B (zh) 2013-12-18
EP3078662A1 (en) 2016-10-12
US20100204240A1 (en) 2010-08-12
MA31779B1 (fr) 2010-10-01
CA2699718C (en) 2014-05-27
MY180558A (en) 2020-12-02
TN2010000100A1 (en) 2011-09-26
BRPI0816881A2 (pt) 2015-03-17
UA101166C2 (ru) 2013-03-11
ES2393824T3 (es) 2012-12-28
CR11383A (es) 2010-08-13
WO2009042435A8 (en) 2009-10-08
EP2573087A1 (en) 2013-03-27
AU2008305294A1 (en) 2009-04-02
KR20100080809A (ko) 2010-07-12
WO2009042435A1 (en) 2009-04-02
CR20150131A (es) 2015-04-30
PL2209778T3 (pl) 2013-02-28
CA2699718A1 (en) 2009-04-02
EP2727910B1 (en) 2016-03-16
JP5722037B2 (ja) 2015-05-20
HRP20120814T1 (hr) 2012-11-30
HK1197821A1 (en) 2015-02-18
SI2209778T1 (sl) 2012-12-31
CN101868459A (zh) 2010-10-20
US8853409B2 (en) 2014-10-07
TWI423799B (zh) 2014-01-21
NZ583538A (en) 2012-06-29
MX2010002772A (es) 2010-03-31
IL204264A (en) 2015-06-30
US20120277242A1 (en) 2012-11-01
TW200914007A (en) 2009-04-01
ES2569734T3 (es) 2016-05-12
EP2727910A1 (en) 2014-05-07
HK1145498A1 (en) 2011-04-21
EP2209778A1 (en) 2010-07-28
US20150057448A1 (en) 2015-02-26
ZA201102350B (en) 2012-09-26
PT2209778E (pt) 2012-12-06
AR068628A1 (es) 2009-11-25
DK2209778T3 (da) 2012-09-17
EA201000515A1 (ru) 2010-10-29
EP2209778B1 (en) 2012-08-29
CO6270223A2 (es) 2011-04-20
JP2010540443A (ja) 2010-12-24
KR101566042B1 (ko) 2015-11-04
EA019104B1 (ru) 2014-01-30

Similar Documents

Publication Publication Date Title
EP2727910B1 (en) Pyridin-2-yl-thiourea and Pyridin-2-yl-amine derivatives as intermediates for the preparation of Pyridin-2yl-amino-1,2,4-thiadiazole glucokinase activators
AP461A (en) "Fungicidal optically active 2-imidazolin-5-one and 2-imidazoline-5-thione derivatives".
AU2012226473B8 (en) Fluoro-pyridinone derivatives useful as antibacterial agents
AU2019269409B2 (en) Matrix metalloproteinase (MMP) inhibitors and methods of use thereof
JPS6089467A (ja) 置換スルホニル尿素、その製法及び用途
KR870001144B1 (ko) 삼환 옥스인돌 카복스아미드 유도체의 제조방법
EP0164247B1 (en) Dihydropyridines
KR920003927B1 (ko) 헤테로사이클릭구아니딘 5ht_3 길항물질
CA2286186A1 (en) Activated iododerivatives for the treatment of cancer and aids
US4859679A (en) Antiulcer (alkyldithio) quinoline derivatives
HUT64759A (en) Method for producing tetrazolyl-(phenoxy-and phenoxy-alkyl-)-pyridinyl-pyridazines
EP0319170B1 (en) Acyl derivatives of hydroxy pyrimidines
EP0082376A2 (en) Substituted derivatives of amino alkane diols as gastric secretion inhibitors
CA1307269C (en) Lankacidin derivatives and production thereof
EP0074820B1 (en) Substituted pyrimid-2-ones, the salts thereof, processes for their preparation and pharmaceutical compositions containing them
JPS60184077A (ja) 抗炎症性オキシム前駆薬
EP0191989A1 (en) Antibiotic isoxazole derivatives, their production and use
SU1371490A3 (ru) Дефолиирующее средство
EP0271550A1 (en) Benzopyran and benzothiopyran derivatives and compositions containing them
JPH07215935A (ja) N−トリクロロアセチル・2−オキシインドール−1−カルボキシアミド
AU2005223325B2 (en) Epothilone derivatives
IE45072B1 (en) Synthesis of 6-(d-2-phenyl-2-(4-pyridyl-formimidoylaminoacetamido)-acetamido)penicillanic acid
KR930001405B1 (ko) 2-(4-치환아미노-3-옥소-이속사졸리디닐)-5-옥소-2-테트라히드로푸란카르복실산 유도체의 제조방법
SU380117A1 (ru) Способ получени N-бета-[тио (фосфорилтиоацетил)]- гидразидов тиофосфорных кислот
EP0254590A2 (en) Aryl-di(thio)ether derivatives as antitumoral pharmaceutical compounds

Legal Events

Date Code Title Description
DA2 Applications for amendment section 104

Free format text: THE NATURE OF THE AMENDMENT IS: AMEND THE INVENTION TITLE TO READ PYRIDIN-2 -YL-AMINO-1, 2, 4 -THIADIAZOLE DERIVATIVES AS GLUCOKINASE ACTIVATORS FOR THE TREATMENT OF DIABETES MELLITUS .

DA3 Amendments made section 104

Free format text: THE NATURE OF THE AMENDMENT IS: AMEND THE INVENTION TITLE TO READ PYRIDIN-2 -YL-AMINO-1, 2, 4 -THIADIAZOLE DERIVATIVES AS GLUCOKINASE ACTIVATORS FOR THE TREATMENT OF DIABETES MELLITUS

FGA Letters patent sealed or granted (standard patent)
MK14 Patent ceased section 143(a) (annual fees not paid) or expired